mianserin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
serotonin receptor antagonists (mostly 5-HT2) 1796 24219-97-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mianserin hydrochloride
  • mianserin
  • mianserine
  • (+/-)-Mianserin
  • mianserine hydrochloride
  • mianserin HCl
  • mianserine HCl
A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
  • Molecular weight: 264.37
  • Formula: C18H20N2
  • CLOGP: 4.01
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -3.06
  • ROTB: 0

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.48 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 21.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.60 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.338 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.449 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 33.420 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 43.351 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 6.050 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 9.900 % High 1
herg hERG pIC50 5.510 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 10.233 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 46.452 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 4.910 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,STK33,TEK,TGFBR1 34
kinase-selectivity-class AXL,PDK4 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.247 High 1
mh-clint Mouse hepatocyte intrinsic clearance 200.447 High 1
mppb Mouse plasma protein binding (% unbound) 6.810 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.509 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 16.670 % High 1
rh-clint Rat hepatocyte intrinsic clearance 259.418 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 25.310 % High 1
rppb Rat plasma protein binding (% unbound) 7.880 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 313.329 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1976 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 277.93 31.77 126 6581 72506 90549234
Hyponatraemia 208.20 31.77 127 6580 133411 90488329
Camptocormia 179.84 31.77 29 6678 264 90621476
Drug interaction 162.56 31.77 146 6561 276307 90345433
Poisoning deliberate 159.73 31.77 56 6651 16430 90605310
Toxicity to various agents 159.44 31.77 147 6560 287699 90334041
Pleurothotonus 158.95 31.77 33 6674 1302 90620438
Fall 156.93 31.77 185 6522 481625 90140115
Agranulocytosis 150.59 31.77 66 6641 34936 90586804
Hepatocellular injury 132.38 31.77 57 6650 28901 90592839
Somnolence 129.87 31.77 114 6593 208970 90412770
Cholestasis 120.04 31.77 57 6650 36242 90585498
Acute kidney injury 119.22 31.77 132 6575 320255 90301485
Altered state of consciousness 108.82 31.77 51 6656 31481 90590259
Drug reaction with eosinophilia and systemic symptoms 99.72 31.77 53 6654 42705 90579035
Bradycardia 98.90 31.77 67 6640 83780 90537960
Bradypnoea 86.80 31.77 26 6681 4632 90617108
Drug abuse 85.84 31.77 61 6646 82286 90539454
Thymus disorder 74.96 31.77 14 6693 316 90621424
Extrapyramidal disorder 70.91 31.77 31 6676 16272 90605468
Wrong patient received product 63.02 31.77 19 6688 3458 90618282
Vertigo 62.07 31.77 47 6660 69764 90551976
Miosis 61.51 31.77 24 6683 9460 90612280
Sedation complication 60.27 31.77 28 6679 16916 90604824
Blood lactic acid 53.31 31.77 9 6698 111 90621629
Housebound 53.11 31.77 10 6697 236 90621504
Suicide attempt 48.46 31.77 42 6665 75357 90546383
Brain death 48.07 31.77 16 6691 4005 90617735
Rash 47.22 31.77 3 6704 796097 89825643
Hepatic cytolysis 46.99 31.77 29 6678 30887 90590853
Traumatic haematoma 46.73 31.77 13 6694 1782 90619958
Oesophageal food impaction 45.25 31.77 9 6698 285 90621455
Inappropriate antidiuretic hormone secretion 44.95 31.77 24 6683 19481 90602259
Cutaneous lymphoma 43.25 31.77 8 6699 171 90621569
Parkinsonism 43.16 31.77 21 6686 14044 90607696
Basilar artery occlusion 42.36 31.77 8 6699 192 90621548
Vertebral artery occlusion 42.05 31.77 8 6699 200 90621540
Morbid thoughts 41.95 31.77 10 6697 744 90620996
Suicidal ideation 41.23 31.77 38 6669 73817 90547923
Hypothermia 41.13 31.77 21 6686 15554 90606186
Drug-device interaction 39.76 31.77 7 6700 112 90621628
Rash maculo-papular 39.59 31.77 29 6678 40904 90580836
Limbic encephalitis 39.26 31.77 8 6699 287 90621453
Eosinophilia 38.94 31.77 25 6682 28508 90593232
Oesophageal achalasia 37.89 31.77 9 6698 659 90621081
Confusional state 37.57 31.77 86 6621 386119 90235621
Respiratory acidosis 37.13 31.77 16 6691 8103 90613637
Hypotension 36.79 31.77 77 6630 325320 90296420
Disturbance in attention 35.97 31.77 29 6678 47080 90574660
Pulmonary embolism 35.47 31.77 46 6661 130774 90490966
Hyperkalaemia 35.44 31.77 33 6674 64931 90556809
Hepatitis 34.91 31.77 34 6673 70705 90551035
Arthralgia 34.01 31.77 8 6699 778514 89843226
Exposure via transplant 33.60 31.77 5 6702 25 90621715
Foetal alcohol syndrome 33.13 31.77 5 6702 28 90621712
Pneumonia aspiration 32.96 31.77 26 6681 40914 90580826
Gamma-glutamyltransferase increased 32.50 31.77 25 6682 37927 90583813

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral artery thrombosis 148.00 27.94 34 5502 1215 42614584
Brain scan abnormal 137.61 27.94 32 5504 1207 42614592
Coma 120.39 27.94 79 5457 53475 42562324
Areflexia 102.56 27.94 32 5504 3711 42612088
Somnolence 95.54 27.94 104 5432 141001 42474798
Ischaemic stroke 81.63 27.94 45 5491 22188 42593611
Poisoning deliberate 81.24 27.94 35 5501 10099 42605700
Hemiplegia 79.27 27.94 32 5504 7847 42607952
Drug interaction 72.00 27.94 126 5410 266873 42348926
Respiratory distress 68.84 27.94 51 5485 41769 42574030
Drug abuse 68.69 27.94 76 5460 104695 42511104
Facial paralysis 64.95 27.94 32 5504 12531 42603268
Hepatocellular injury 63.26 27.94 39 5497 23639 42592160
Hepatic cytolysis 49.30 27.94 35 5501 26809 42588990
Altered state of consciousness 48.84 27.94 36 5500 29223 42586576
Withdrawal syndrome 46.36 27.94 27 5509 14748 42601051
Reticulocytosis 45.52 27.94 10 5526 290 42615509
Agranulocytosis 45.19 27.94 35 5501 30577 42585222
Painful ejaculation 44.66 27.94 9 5527 170 42615629
Adenomatous polyposis coli 44.41 27.94 9 5527 175 42615624
Poikiloderma 44.40 27.94 10 5526 326 42615473
Dissociative disorder 42.30 27.94 11 5525 661 42615138
Reduced facial expression 41.54 27.94 13 5523 1520 42614279
Wrong patient received product 41.09 27.94 16 5520 3567 42612232
Disease recurrence 39.65 27.94 32 5504 29646 42586153
Cholestasis 38.82 27.94 33 5503 32846 42582953
Gallbladder injury 37.87 27.94 8 5528 192 42615607
Cardio-respiratory arrest 37.43 27.94 42 5494 58594 42557205
Fear 36.97 27.94 21 5515 10944 42604855
Anti-platelet antibody positive 35.22 27.94 8 5528 271 42615528
Coombs direct test positive 33.51 27.94 8 5528 338 42615461
Lichenoid keratosis 32.82 27.94 14 5522 3936 42611863
Initial insomnia 32.55 27.94 14 5522 4016 42611783
Blood bilirubin unconjugated increased 32.52 27.94 9 5527 686 42615113
Pneumonia aspiration 32.18 27.94 36 5500 50042 42565757
Meningioma 32.05 27.94 11 5525 1716 42614083
Haptoglobin decreased 32.01 27.94 9 5527 727 42615072
Drug dependence 31.91 27.94 28 5508 29066 42586733
Blood glucose fluctuation 30.81 27.94 14 5522 4573 42611226
Drug-disease interaction 29.96 27.94 9 5527 917 42614882
Benign soft tissue neoplasm 29.45 27.94 6 5530 120 42615679
Panic attack 28.99 27.94 18 5518 11027 42604772
Painful erection 28.29 27.94 7 5529 344 42615455

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 371.32 24.72 204 12046 117665 110459384
Poisoning deliberate 242.69 24.72 96 12154 26235 110550814
Somnolence 228.28 24.72 218 12032 297231 110279818
Drug interaction 214.92 24.72 270 11980 499913 110077136
Hepatocellular injury 176.90 24.72 94 12156 50548 110526501
Agranulocytosis 175.42 24.72 100 12150 61660 110515389
Camptocormia 153.35 24.72 29 12221 459 110576590
Hyponatraemia 150.81 24.72 151 12099 217502 110359547
Altered state of consciousness 144.30 24.72 86 12164 57540 110519509
Cholestasis 142.88 24.72 89 12161 64429 110512620
Fall 138.75 24.72 243 12007 603239 109973810
Drug abuse 137.67 24.72 131 12119 177280 110399769
Cerebral artery thrombosis 133.17 24.72 32 12218 1636 110575413
Brain scan abnormal 129.87 24.72 31 12219 1540 110575509
Toxicity to various agents 126.96 24.72 206 12044 480349 110096700
Pleurothotonus 120.34 24.72 32 12218 2466 110574583
Acute kidney injury 112.58 24.72 229 12021 635201 109941848
Hepatic cytolysis 97.43 24.72 66 12184 54987 110522062
Wrong patient received product 96.95 24.72 34 12216 6640 110570409
Drug reaction with eosinophilia and systemic symptoms 94.64 24.72 76 12174 82019 110495030
Ischaemic stroke 91.52 24.72 57 12193 41206 110535843
Bradycardia 89.87 24.72 98 12152 155419 110421630
Respiratory distress 88.53 24.72 68 12182 68806 110508243
Areflexia 85.17 24.72 31 12219 6738 110570311
Extrapyramidal disorder 77.26 24.72 45 12205 28822 110548227
Miosis 71.66 24.72 39 12211 21944 110555105
Suicide attempt 68.31 24.72 70 12180 103324 110473725
Bradypnoea 64.13 24.72 27 12223 8622 110568427
Pneumonia aspiration 62.94 24.72 60 12190 81173 110495876
Thymus disorder 61.31 24.72 14 12236 572 110576477
Withdrawal syndrome 58.82 24.72 39 12211 31341 110545708
Arthralgia 55.04 24.72 10 12240 779622 109797427
Vertigo 52.34 24.72 56 12194 86814 110490235
Suicidal ideation 52.15 24.72 58 12192 93879 110483170
Hemiplegia 51.84 24.72 32 12218 22750 110554299
Cardio-respiratory arrest 51.79 24.72 64 12186 115772 110461277
Painful ejaculation 50.54 24.72 9 12241 100 110576949
Confusional state 50.12 24.72 139 12111 468541 110108508
Facial paralysis 50.05 24.72 32 12218 24182 110552867
Sedation complication 48.02 24.72 29 12221 19826 110557223
Hypotension 47.99 24.72 147 12103 523702 110053347
Disturbance in attention 44.65 24.72 44 12206 61951 110515098
Rash 44 24.72 18 12232 820946 109756103
Rash maculo-papular 43.22 24.72 47 12203 74175 110502874
Housebound 42.78 24.72 10 12240 453 110576596
Behaviour disorder 42.63 24.72 21 12229 9626 110567423
Poikiloderma 42.18 24.72 10 12240 482 110576567
Dissociative disorder 41.68 24.72 12 12238 1239 110575810
Traumatic haematoma 41.65 24.72 14 12236 2407 110574642
Adenomatous polyposis coli 40.60 24.72 9 12241 321 110576728
Hypothermia 40.58 24.72 29 12221 26273 110550776
Reticulocytosis 39.57 24.72 10 12240 630 110576419
Gamma-glutamyltransferase increased 39.56 24.72 41 12209 61268 110515781
Drug hypersensitivity 38.93 24.72 3 12247 454087 110122962
Drug dependence 38.84 24.72 37 12213 49983 110527066
Brain death 37.30 24.72 17 12233 6556 110570493
Blood lactic acid 37.28 24.72 9 12241 469 110576580
Pain in extremity 37.16 24.72 5 12245 487113 110089936
Drug-device interaction 36.38 24.72 7 12243 122 110576927
Cutaneous lymphoma 36.29 24.72 8 12242 278 110576771
Headache 36.21 24.72 27 12223 882350 109694699
Morbid thoughts 35.98 24.72 10 12240 909 110576140
Basilar artery occlusion 35.91 24.72 8 12242 292 110576757
Oesophageal food impaction 35.75 24.72 9 12241 558 110576491
Overdose 35.12 24.72 79 12171 233715 110343334
Anti-platelet antibody positive 34.68 24.72 8 12242 342 110576707
Dyspnoea 33.77 24.72 44 12206 1106828 109470221
Fear 32.22 24.72 24 12226 23169 110553880
Painful erection 31.96 24.72 7 12243 236 110576813
Vertebral artery occlusion 31.81 24.72 8 12242 494 110576555
Lichenoid keratosis 31.72 24.72 15 12235 6287 110570762
Exposure via transplant 31.59 24.72 5 12245 25 110577024
Coombs direct test positive 31.33 24.72 8 12242 525 110576524
Parkinsonism 30.91 24.72 23 12227 22164 110554885
Oesophageal achalasia 30.51 24.72 9 12241 1012 110576037
Initial insomnia 29.94 24.72 17 12233 10372 110566677
Benign soft tissue neoplasm 29.90 24.72 6 12244 131 110576918
Disease recurrence 29.46 24.72 35 12215 60749 110516300
Poisoning 29.45 24.72 25 12225 29080 110547969
Blood bilirubin unconjugated increased 29.21 24.72 9 12241 1172 110575877
Peripheral swelling 28.86 24.72 5 12245 404029 110173020
Infusion related reaction 28.86 24.72 4 12246 381158 110195891
Generalised anxiety disorder 28.65 24.72 11 12239 2768 110574281
Hepatitis 28.40 24.72 42 12208 90012 110487037
Rhabdomyolysis 28.15 24.72 49 12201 120352 110456697
Inappropriate antidiuretic hormone secretion 28.12 24.72 26 12224 33825 110543224
Limbic encephalitis 28.04 24.72 8 12242 800 110576249
Single umbilical artery 27.72 24.72 4 12246 9 110577040
Electrocardiogram QT prolonged 27.66 24.72 46 12204 108914 110468135
Pneumonia 27.59 24.72 34 12216 876680 109700369
Hypersensitivity 26.76 24.72 6 12244 403992 110173057
Hallucination, visual 26.47 24.72 27 12223 39578 110537471
Pain 26.09 24.72 41 12209 954914 109622135
Neuroleptic malignant syndrome 26.07 24.72 25 12225 34034 110543015
Blood glucose fluctuation 26.04 24.72 14 12236 7684 110569365
Haptoglobin decreased 25.78 24.72 9 12241 1732 110575317
Reduced facial expression 25.74 24.72 11 12239 3640 110573409
Persecutory delusion 25.74 24.72 13 12237 6278 110570771
Cerebral haematoma 25.72 24.72 15 12235 9617 110567432
Fatigue 25.60 24.72 61 12189 1215897 109361152
Respiratory acidosis 25.46 24.72 17 12233 13809 110563240
Disorientation 25.28 24.72 35 12215 70636 110506413
Drug intolerance 25.06 24.72 7 12243 406505 110170544
Penile pain 25.02 24.72 8 12242 1176 110575873
Drug-disease interaction 24.85 24.72 9 12241 1927 110575122
Frontotemporal dementia 24.77 24.72 7 12243 676 110576373
Infection 24.76 24.72 5 12245 362195 110214854

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX03 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D000928 Antidepressive Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D011619 Psychotropic Drugs
MeSH PA D012702 Serotonin Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018687 Antidepressive Agents, Second-Generation
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35640 adrenergic uptake inhibitor
CHEBI has role CHEBI:35678 histamine agonist
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:37890 ฮฑ-adrenergic antagonist
CHEBI has role CHEBI:37955 H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:76779 EC 3.4.21.26 (prolyl oligopeptidase) inhibitor

Related Drugs by ATC class:

N06AX Other antidepressants 28 drugs
agomelatinebifemelanebrexanolonebupropiondesvenlafaxinedextromethorphanduloxetineesketaminegepironelevomilnacipranmedifoxaminemilnacipran show all 28 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.2 Basic
pKa2 1.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.52 WOMBAT-PK IUPHAR
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 8.12 WOMBAT-PK IUPHAR
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.17 WOMBAT-PK IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 8.32 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.40 PDSP
Sodium-dependent noradrenaline transporter Transporter Kd 7.15 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.13 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.18 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.06 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR IC50 6.39 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.57 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 5.55 CHEMBL
Histamine H1 receptor GPCR Ki 9.25 WOMBAT-PK
Histamine H2 receptor GPCR Ki 6.00 DRUG MATRIX
Histamine H4 receptor GPCR EC50 6.13 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 6.47 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 6.42 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.53 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.54 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.64 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 7.53 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 6.99 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 8.42 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.03 PDSP
D(4) dopamine receptor GPCR IC50 5.48 CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 7.50 IUPHAR
5-hydroxytryptamine receptor 3A Ion channel Ki 6.21 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 7.40 IUPHAR
5-hydroxytryptamine receptor 1F GPCR Ki 8.06 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.26 CHEMBL
D(1A) dopamine receptor GPCR Ki 6 WOMBAT-PK
D(2) dopamine receptor GPCR Ki 5.66 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.18 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.33 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 10.15 CHEMBL
Histamine H1 receptor GPCR Ki 9.07 CHEMBL
D(2) dopamine receptor GPCR Ki 6.08 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 5.54 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.82 CHEMBL
Transporter Transporter Ki 7.59 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.20 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7 IUPHAR
D(1A) dopamine receptor GPCR Ki 5.85 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 8.85 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.37 CHEMBL
D(3) dopamine receptor GPCR Ki 5.82 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.77 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR IC50 5.72 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.40 IUPHAR
Serotonin 3 (5-HT3) receptor Ion channel Ki 7.15 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 6.24 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.21 CHEMBL
Cerebral cortex alpha adrenergic receptor GPCR IC50 8.22 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 8.96 CHEMBL
Serotonin 3 receptor (5HT3) Ion channel Ki 6.60 CHEMBL
G-protein coupled receptor GPCR IC50 4.14 CHEMBL
5-hydroxytryptamine receptor 1B GPCR ANTAGONIST Ki 8.30 IUPHAR

External reference:

IDSource
D01358 KEGG_DRUG
21535-47-7 SECONDARY_CAS_RN
4027429 VANDF
C0025912 UMLSCUI
CHEBI:51137 CHEBI
WRU PDB_CHEM_ID
CHEMBL6437 ChEMBL_ID
CHEMBL544428 ChEMBL_ID
DB06148 DRUGBANK_ID
D008803 MESH_DESCRIPTOR_UI
4184 PUBCHEM_CID
135 IUPHAR_LIGAND_ID
2543 INN_ID
250PJI13LM UNII
203127 RXNORM
18113 MMSL
004006 NDDF
004007 NDDF
387565003 SNOMEDCT_US
395795008 SNOMEDCT_US
96200003 SNOMEDCT_US
250PJI13LM INXIGHT DRUGS

Pharmaceutical products:

None